Posted by Michael Wonder on 14 Aug 2024
Lynparza and Imfinzi combination approved in the EU for patients with mismatch repair proficient advanced or recurrent endometrial cancer
14 August 2024 - First immunotherapy and PARP inhibitor combination approved in endometrial cancer.
AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as a first-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch repair proficient disease. Imfinzi plus chemotherapy followed by Imfinzi alone has been approved for patients with mismatch repair deficient disease.
